keyword
MENU ▼
Read by QxMD icon Read
search

Macular oedema

keyword
https://www.readbyqxmd.com/read/28432581/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-macular-oedema-due-to-branch-retinal-vein-occlusion-a-pilot-study
#1
M A Khan, Varakutti Mallika, Dattakiran Joshi
PURPOSE: To compare visual and anatomical recovery of immediate versus deferred intravitreal Bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO). METHODS: In a pilot study, 40 treatment naïve patients of branch retinal vein occlusion with macular oedema and vision 6/12 or less presenting within one month of onset were randomised into 2 groups (20 each) to receive either immediate intravitreal Bevacizumab or deferred (after 3 months of observation)...
April 21, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28432109/early-response-to-ranibizumab-predictive-of-functional-outcome-after-dexamethasone-for-unresponsive-diabetic-macular-oedema
#2
Maria Vittoria Cicinelli, Michele Cavalleri, Lea Querques, Alessandro Rabiolo, Francesco Bandello, Giuseppe Querques
PURPOSE: To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular endothelial growth factor (VEGF) loading dose, in order to early shift to corticosteroids in poorly responding patients. DESIGN: Retrospective monocentric study. METHODS: Data of patients with diabetes shifted to 0.7 mg dexamethasone implant after three injections of ranibizumab (RNB) and followed-up to 12 months were reviewed...
April 21, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28421654/short-term-outcomes-of-small-incision-cataract-surgery-provided-by-a-regional-population-in-the-pacific
#3
Riyaz Bhikoo, Hans Vellara, Salome Lolokabaira, Neil Murray, Biu Sikivou, Charles McGhee
BACKGROUND: To describe patient demographics, visual and surgical outcomes of a cohort undergoing Small Incision Cataract Surgery (SICS) at a Pacific regional ophthalmic training facility. DESIGN: Prospective, longitudinal study conducted at the Pacific Eye Institute, Fiji. PARTICIPANTS: 156 patients underwent SICS. METHODS: Preoperatively, a complete ophthalmic examination, including pachymetry and macular Optical Coherence Tomography (OCT) performed by two independent investigators...
April 19, 2017: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/28416492/intravitreal-triamcinolone-acetate-for-radiation-maculopathy-recalcitrant-to-high-dose-intravitreal-bevacizumab
#4
Richard I Kaplan, Sonal S Chaugule, Paul T Finger
BACKGROUND/AIMS: To evaluate the effect of adjuvant intravitreal triamcinolone acetonide (ITA) for radiation maculopathy (RM) recalcitrant to high-dose bevacizumab in patients with choroidal melanoma after plaque radiotherapy. METHODS: Eight eyes of eight patients with RM secondary to plaque radiotherapy for choroidal melanoma, recalcitrant to high-dose bevacizumab (3.0 mg) were retrospectively evaluated. Intravitreal injections of ITA (4 mg/0.1 mL) were performed at 4-week to 16-week intervals as an adjunct to continued bevacizumab therapy...
April 17, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28405787/outcomes-of-switching-treatment-to-aflibercept-in-patients-with-macular-oedema-secondary-to-central-retinal-vein-occlusion-refractory-to-ranibizumab
#5
Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T Tsaousis, Konstantina Gorgoli, Somnath Banerjee, Theodoros Empeslidis
PURPOSE: To assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO). METHODS: A prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection...
April 12, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28404670/intravitreal-dexamethasone-implant-in-radiation-induced-macular-oedema
#6
Luisa Frizziero, Raffaele Parrozzani, Sara Trainiti, Elisabetta Pilotto, Giacomo Miglionico, Serena Pulze, Edoardo Midena
AIMS: To evaluate the efficacy and duration of activity of a single intravitreal dexamethasone implant in patients affected by radiation maculopathy. METHODS: Thirteen consecutive eyes of 13 patients affected by radiation maculopathy secondary to eye irradiation for a primary uveal melanoma (Iodine-125 brachytherapy) and treated with a single intravitreal 0.7 mg dexamethasone implant were retrospectively evaluated. Each patient underwent full ophthalmological examination, including fluorescein angiography and spectral domain optical coherence tomography (SD-OCT), even in en-face modality...
April 12, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28399772/nurse-led-ranibizumab-intravitreal-injections-in-wet-age-related-macular-degeneration-a-literature-review
#7
Emma Gregg
Aim The aim of this literature review was to explore the development of the role of specialist ophthalmic nurses in delivering ranibizumab intravitreal injections to patients with wet age-related macular degeneration (AMD), and to evaluate their contribution to reducing capacity pressures in medical retina services, while maintaining safe and effective standards of care. Method A systematic literature search was undertaken to identify relevant articles published between January 2000 and June 2015. A search of electronic databases was undertaken, and selected relevant journals were searched manually...
April 12, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28395937/risk-factors-for-diabetic-macular-oedema-in-type-2-diabetes-a-case-control-study-in-a-united-kingdom-primary-care-setting
#8
E Martín-Merino, J Fortuny, E Rivero-Ferrer, M Lind, L A Garcia-Rodriguez
AIM: To identify risk factors associated with the development of DMO among patients diagnosed with type 2 diabetes managed in a primary care setting in the UK. METHODS: A case-control study nested in a cohort of incident Type 2 diabetes identified in The Health Improvement Network database from 2000-2007. Cases were people with DMO (N=211) and controls were a DMO-free sample (N=2194). No age restrictions were applied. Adjusted odds ratios and 95%CIs were estimated (OR; 95%CI)...
April 7, 2017: Primary Care Diabetes
https://www.readbyqxmd.com/read/28378980/subthreshold-micropulse-yellow-577-nm-laser-therapy-of-diabetic-macular-oedema-in-rural-and-urban-patients-of-south-eastern-poland
#9
Małgorzata Latalska, Agata Prokopiuk, Dominika Wróbel-Dudzińska, Jerzy Mackiewicz
Objectiv. To evaluate the efficacy of subthreshold micropulse yellow (577 nm) laser photocoagulation in diffuse macular edema (DME) in rural and urban patients of south-eastern Poland. MATERIALS AND METHOD: Seventy-five eyes of 75 patients with diffuse DME were treated with subthreshold micropulse yellow laser photocoagulation with a 5% duty cycle at an energy level. The laser exposure time was 20 ms and the spot diameter was 100 μm. Best corrected visual acuity (BCVA), reading vision (Snellen) and optical coherence tomography-determined central retinal thickness (CRT) were estimated before and 2, 4 and 6 months after laser treatment...
March 21, 2017: Annals of Agricultural and Environmental Medicine: AAEM
https://www.readbyqxmd.com/read/28376554/-retinal-vein-occlusion-which-treatment-when
#10
A Bajor, A Pielen, L Danzmann
According to the latest findings, macular oedema due to retinal vein occlusion is best treated safely and effectively with near-term intravitreal anti-VEGF therapy (aflibercept, bevacizumab [off label], ranibizumab). After an initial upload of 3 monthly injections of anti-VEGF, the decision on re-injection should be based on OCT (rather than on visual acuity). After initial monthly injections, the "pro-re-nata" (PRN) and the "treat-and-extend" regimens have been predominantly used in the further course of therapy...
April 4, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28365905/aflibercept-a-review-in-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#11
Sheridan M Hoy
Aflibercept (Eylea(®)) is a fully human, recombinant fusion protein available in various countries worldwide, including those of the EU, as well as the USA, for intravitreal use in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) in adults. Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor (VEGF)-A and placental growth factor (PIGF), preventing these angiogenic factors from binding to and activating their cognate receptors...
April 1, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28318344/clinical-outcomes-of-intravitreal-preservative-free-triamcinolone-preparation-triesence%C3%A2-for-cystoid-macular-oedema-and-inflammation-in-patients-with-uveitis
#12
Laura R Steeples, Nitin Anand, Jiten Moraji, Nicholas P Jones
PURPOSE: To assess the outcomes of intravitreal benzyl alcohol-free triamcinolone acetonide suspension in uveitis-related macular oedema. METHODS: Single-center retrospective cohort study of 66 injections to 44 eyes of 40 patients. Uveitis diagnosis, systemic and local therapy, intraocular pressure (IOP), central retinal thickness (CRT), number of injections, time to re-injection and side-effects were noted during 6-months minimum follow-up. RESULTS: Sixty eight percent of eyes received a single injection...
March 20, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28303988/cystoid-macular-oedema-after-phacoemulsification-with-and-without-type-2-diabetes-mellitus-a-hospital-based-clinical-prospective-trial-in-karachi
#13
Abdul Haleem, Adil Saleem, Saleh Memon, Nasir Memon, Muhammad Faisal Fahim
OBJECTIVE: To know the outcomes of cystoid macular oedema after phacoemulsification in patients with and without type 2 diabetes mellitus using optical coherence tomography. METHODS: This non-concurrent, clinical, prospective study was carried out at Al-Ibrahim Eye Hospital, Karachi, from January to August 2015. After phacoemulsification with injectable posterior chamber intraocular lens implantation, eyes of patients were analysed. The patients were divided into diabetic and non-diabetic groups visual acuity, optical coherence tomography and dilated fundus examination were performed preoperatively (baseline) and post-operative 1st week and 6th week...
March 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28282065/fundus-autofluorescence-imaging-systematic-review-of-test-accuracy-for-the-diagnosis-and-monitoring-of-retinal-conditions
#14
REVIEW
G K Frampton, N Kalita, L Payne, J L Colquitt, E Loveman, S M Downes, A J Lotery
We conducted a systematic review of the accuracy of fundus autofluorescence (FAF) imaging for diagnosing and monitoring retinal conditions. Searches in November 2014 identified English language references. Sources included MEDLINE, EMBASE, the Cochrane Library, Web of Science, and MEDION databases; reference lists of retrieved studies; and internet pages of relevant organisations, meetings, and trial registries. For inclusion, studies had to report FAF imaging accuracy quantitatively. Studies were critically appraised using QUADAS risk of bias criteria...
March 10, 2017: Eye
https://www.readbyqxmd.com/read/28270488/aqueous-cytokine-and-growth-factor-levels-indicate-response-to-ranibizumab-for-diabetic-macular-oedema
#15
Masahiko Shimura, Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Hidetaka Noma
BACKGROUND/AIMS: To investigate the relations between aqueous humour levels of cytokines/growth factors and treatment response to intravitreal ranibizumab (IVR) for diabetic macular oedema (DME) METHODS: Sixty-eight eyes of 68 patients with treatment-naïve centre-involved DME, central macular thickness (CMT) greater than 400 μm and visual acuity (VA) worse than logMAR 0.3 were recruited. Each patient received monthly IVR injection (0.5 mg/0.05 mL) until CMT was reduced to below 300 μm...
March 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28270484/differences-in-incidence-of-diabetic-retinopathy-between-type-1-and-2-diabetes-mellitus-a-nine-year-follow-up-study
#16
Pedro Romero-Aroca, Raul Navarro-Gil, Aida Valls-Mateu, Ramon Sagarra-Alamo, Antonio Moreno-Ribas, Nuria Soler
BACKGROUND/AIMS: To determine the incidence of any diabetic retinopathy (any-DR), sight-threatening diabetic retinopathy (STDR) and diabetic macular oedema (DMO) and their risk factors in type 1 diabetes mellitus (T1DM) over a screening programme. METHODS: Nine-year follow-up, prospective population-based study of 366 patients with T1DM and 15 030 with T2DM. Epidemiological risk factors were as follows: current age, age at DM diagnosis, sex, type of DM, duration of DM, arterial hypertension, levels of glycosylated haemoglobin (HbA1c), triglycerides, cholesterol fractions, serum creatinine, estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR)...
March 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28266152/macular-cystic-changes-as-predictive-factor-for-the-recurrence-of-macular-oedema-in-branch-retinal-vein-occlusion
#17
Eric Tilgner, Maiara Dalcegio Favretto, Maria Tuisl, Peter Wiedemann, Matus Rehak
AIM: To evaluate the role of small cystic macular changes as a prognostic factor for the recurrence of macular oedema (ME) in patients with branch retinal vein occlusion (BRVO) treated with anti-VEGF drugs. METHODS: We performed retrospective chart analysis of 116 patients treated with intravitreal injection of ranibizumab (IVR) or bevacizumab (IVB) for ME secondary to BRVO. At the baseline and monthly follow-up visits over a period of 12 months, a comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA) and volume scan of macula using Spectral domain optical coherence tomography (SD-OCT) were performed...
March 7, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28258075/a-retrospective-study-of-the-influence-of-the-vitreomacular-interface-on-macular-oedema-secondary-to-retinal-vein-occlusion
#18
Rishi P Singh, Karishma A Habbu, Rumneek Bedi, Fabiana Q Silva, Justis P Ehlers, Andrew P Schachat, Jonathan E Sears, Sunil K Srivastava, Peter K Kaiser, Alex Yuan
AIMS: To compare anti-vascular endothelial growth factor (VEGF) treatment outcomes for macular oedema (ME) secondary to retinal vein occlusion (RVO) based on vitreoretinal interface (VRI) status. METHODS: This retrospective case series includes treatment-naive eyes diagnosed with RVO and treated with anti-VEGF injections. Eyes were stratified based on international VRI classification schema at baseline into three groups-vitreomacular traction (group A), no posterior vitreous detachment (PVD) (group B) and PVD without vitreomacular attachment (group C)...
March 3, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28251811/head-to-head-comparison-of-ranibizumab-prn-versus-single-dose-dexamethasone-for-branch-retinal-vein-occlusion-comrade-b
#19
Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, Steffen Schmitz-Valckenberg, Hüsnü Berk, Nicole Eter, Gabriele E Lang, Matus Rehak, Simon R Taylor, Armin Wolf, Claudia Weiss, Eva-Maria Paulus, Amelie Pielen, Hans Hoerauf
PURPOSE: To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg according to their European labels in macular oedema secondary to branch retinal vein occlusion (BRVO) in a 6-month, phase IIIb, randomized trial. METHODS: Patients received either monthly ranibizumab for 3 months followed by Pro re nata (PRN) treatment (n = 126) or a sustained-release dexamethasone implant followed by PRN sham injections (n = 118). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean changes in BCVA and foveal centre point thickness (FCPT), and adverse events (AEs)...
March 2, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28228411/retinal-vascular-calibre-changes-after-intravitreal-bevacizumab-or-dexamethasone-implant-treatment-for-diabetic-macular-oedema
#20
Sanjeewa S Wickremasinghe, Samantha Fraser-Bell, Elizabeth Alessandrello, Hemal Mehta, Mark C Gillies, Lyndell L Lim
PURPOSE: To compare changes in retinal vascular calibre after 2 years of treatment with intravitreal bevacizumab (BVZ) or dexamethasone implant (DEX) in patients with centre-involving diabetic macular oedema (DMO). METHODS: At baseline, 88 eyes of 61 patients with DMO were recruited in a prospective, multicentre, randomised, single-masked clinical trial. Of these subjects, 22 BVZ-treated (52%) and 22 DEX-treated (48%) eyes of 34 patients (56%) had gradable retinal photographs at both the baseline and 24-month visits...
February 22, 2017: British Journal of Ophthalmology
keyword
keyword
102386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"